Please select the option that best describes you:

What treatment options would you consider for a patient with an ECOG PS of 0 with metastatic non-uterine leiomyosarcoma who has progressed on all standard systemic therapies including anthracycline, gemcitabine, taxane, vinorelbine, pazopanib, temozolomide, and trabectidin?

Are there clinic trials that look promising for patients with leiomyosarcoma?

Answer from: Medical Oncologist at Academic Institution

The correct answer is a phase 1 clinical trial, or perhaps compassionate use immunotherapy.

Comments

Medical Oncologist at Texas Oncology
Emanated from the IVC wall on presentation

Answer from: Medical Oncologist at Academic Institution

I would agree but add one other options. Though not based on the strict FDA indication, Doxorubicin plus PDGFR antibody OLARATUMAB is approved as first line therapy --since your patient didnt have access to newly approved Olaratumab first line, you could use this regimen. Caveats re: cum...

Please select the option that best describes you:

What treatment options would you consider for a patient with an ECOG PS of 0 with metastatic non-uterine leiomyosarcoma who has progressed on all standard systemic therapies including anthracycline, gemcitabine, taxane, vinorelbine, pazopanib, temozolomide, and trabectidin?

Related Questions